EI
PDSB icon

EAM Investors’s PDS Biotechnology PDSB Stock Holding History

EAM Investors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-330,426
Closed -$4.36M – 337
2022
Q4 		$4.36M Buy
+330,426
New +$2.33M 0.9% 6
2021
Q4 		– Sell
-258,769
Closed -$3.86M – 353
2021
Q3 		$3.86M Sell
258,769
-20,844
-7% -$260K 0.65% 26
2021
Q2 		$3.51M Buy
+279,613
New +$2.18M 0.54% 39

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's PDSB Position: Q1 2023 in Review

EAM Investors sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 330,426 shares — an estimated $4.36M sold.

EAM Investors first reported a position in PDSB in Q2 2021 and held it in 3 quarters. The position peaked at $4.36M in Q4 2022. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

  • EAM Investors reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
  • EAM Investors sold 330,426 PDS Biotechnology shares in Q1 2023, an estimated $4.36M.
  • EAM Investors first reported a position in PDS Biotechnology in Q2 2021 and held it in 3 quarters.
  • EAM Investors's PDS Biotechnology position peaked at $4.36M in Q4 2022.
  • 68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.